Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia
- PMID: 31723042
- PMCID: PMC6883801
- DOI: 10.1073/pnas.1913695116
Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia
Abstract
Chronic lymphocytic leukemia (CLL) is the most common human leukemia, and dysregulation of tRNA-derived short noncoding RNA (tsRNA) (tRF-1) expression is an accompanying event in the development of this disease. tsRNAs are fragments originating from the 3' end of tRNA precursors and do not contain mature tRNA sequences. In contrast to tsRNAs, mature tRFs (tRF-3s, tRF-5s, and internal tRFs) are produced from mature tRNA sequences and are redundant fragments. We investigated tsRNA expression in CLL and determined tsRNA signatures in indolent CLL and aggressive CLL vs. normal B cells. We noticed that both ts-43 and ts-44 are derived from distinct genes of pre-tRNAHis, and are down-regulated in CLL 3- to 5-fold vs. normal B cells. Thus, we investigated expression levels of tRF-5 fragments from tRNAHis in CLL samples and healthy controls, and determined that such fragments are down-regulated by 5-fold in CLLs vs. normal controls. Given these results, we investigated the expression of all mature tRFs in CLLs vs. normal controls. We found a drastic dysregulation of the expression of mature tRFs in CLL. In aggressive CLL, for the top 15 up-regulated fragments, linear fold change varied from 2,053- to 622-fold. For the top 15 down-regulated fragments in CLL, linear fold change varied from 314- to 52-fold. In addition, 964 mature tRFs were up-regulated at least 2-fold in CLL, while 701 fragments were down-regulated at least 2-fold. Similar results were obtained for indolent CLL. Our results suggest that mature tRFs may have oncogenic and/or tumor suppressor function in CLL.
Keywords: tRFs; tRNA fragments; tsRNAs.
Conflict of interest statement
Competing interest statement: N.C. and T.J.K. are coauthors on a 2018 guidelines paper. N.C. and C.M.C. are coinvestigators on a grant application but have not begun a collaboration yet.
Figures
Similar articles
-
Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.Proc Natl Acad Sci U S A. 2016 May 3;113(18):5071-6. doi: 10.1073/pnas.1604266113. Epub 2016 Apr 11. Proc Natl Acad Sci U S A. 2016. PMID: 27071132 Free PMC article.
-
A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia.Clin Biochem. 2020 Nov;85:20-26. doi: 10.1016/j.clinbiochem.2020.07.005. Epub 2020 Aug 1. Clin Biochem. 2020. PMID: 32745483
-
tRNA-derived fragments: Mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections.Theranostics. 2021 Jan 1;11(1):461-469. doi: 10.7150/thno.51963. eCollection 2021. Theranostics. 2021. PMID: 33391486 Free PMC article. Review.
-
tRNA-derived fragments and tRNA halves: The new players in cancers.Cancer Lett. 2019 Jun 28;452:31-37. doi: 10.1016/j.canlet.2019.03.012. Epub 2019 Mar 21. Cancer Lett. 2019. PMID: 30905816
-
tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation.Cell Mol Life Sci. 2021 Mar;78(6):2607-2619. doi: 10.1007/s00018-020-03720-7. Epub 2021 Jan 2. Cell Mol Life Sci. 2021. PMID: 33388834 Review.
Cited by
-
The Emerging Function and Promise of tRNA-Derived Small RNAs in Cancer.J Cancer. 2024 Jan 27;15(6):1642-1656. doi: 10.7150/jca.89219. eCollection 2024. J Cancer. 2024. PMID: 38370372 Free PMC article. Review.
-
tRFUniverse: A comprehensive resource for the interactive analyses of tRNA-derived ncRNAs in human cancer.iScience. 2024 Jan 5;27(2):108810. doi: 10.1016/j.isci.2024.108810. eCollection 2024 Feb 16. iScience. 2024. PMID: 38303722 Free PMC article.
-
Transfer RNAs as dynamic and critical regulators of cancer progression.Nat Rev Cancer. 2023 Nov;23(11):746-761. doi: 10.1038/s41568-023-00611-4. Epub 2023 Oct 9. Nat Rev Cancer. 2023. PMID: 37814109 Review.
-
The essential roles of small non-coding RNAs and RNA modifications in normal and malignant hematopoiesis.Front Mol Biosci. 2023 Mar 31;10:1176416. doi: 10.3389/fmolb.2023.1176416. eCollection 2023. Front Mol Biosci. 2023. PMID: 37065445 Free PMC article. Review.
-
The role and mechanism of action of tRNA-derived fragments in the diagnosis and treatment of malignant tumors.Cell Commun Signal. 2023 Mar 24;21(1):62. doi: 10.1186/s12964-023-01079-3. Cell Commun Signal. 2023. PMID: 36964534 Free PMC article. Review.
References
-
- Döhner H., et al. , Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910–1916 (2000). - PubMed
-
- Rassenti L. Z., et al. , ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351, 893–901 (2004). - PubMed
-
- Herling M., et al. , TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20, 280–285 (2006). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
